Archiv
Archiv anzeigen:
bis


VTE Recurrence After Negative D-Dimer Testing

Brady L. Stein, MD, MHS reviewing Kearon C et al. J Thromb Haemost 2019 Apr 29

The 5-year risk for recurrence was nearly 30% in men with unprovoked venous thromboembolism, despite negative D-dimer testing.


Atezolizumab plus Bevacizumab for Advanced Renal Cell Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Rini BI et al. Lancet 2019 May 9, Pilié PG and Jonasch E. Lancet 2019 May 9

Progression-free survival and safety were better with this combination therapy than with standard sunitinib treatment.


The Impact of Prediagnosis 5-ARIs on Men with Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Sarkar RR et al. JAMA Intern Med 2019 May 6

Use of 5α-reductase inhibitors was associated with delayed diagnosis and worse mortality.


Platelet Autoantibody Testing for Immune Thrombocytopenia

Brady L. Stein, MD, MHS reviewing Vrbensky JR et al. J Thromb Haemost 2019 May

Specificity was high, but sensitivity was low; thus, autoantibody testing may rule in but not rule out ITP.


Targeting Myeloma with CAR T-Cells

Michael E. Williams, MD, ScM reviewing Raje N et al. N Engl J Med 2019 May 2

Relapsed or refractory patients had high response rates with anticipated, manageable toxicities.


Erythropoiesis-Stimulating Agents for Cancer-Associated Anemia

Brady L. Stein, MD, MHS reviewing Bohlius J et al. Blood Adv 2019 Apr 23

An update to 2010 guidelines


Unique Therapy for a Rare Blood Cancer

Michael E. Williams, MD, ScM reviewing Pemmaraju N et al. N Engl J Med 2019 Apr 25

Patients with untreated or relapsed blastic plasmacytoid dendritic-cell neoplasm achieved high response rates with tagraxofusp, a novel targeted cytotoxin.


Vitamin D Cancer Therapy?

David H. Ilson, MD, PhD reviewing Urashima M et al. JAMA 2019 Apr 9, Ng K et al. JAMA 2019 Apr 9, Barry EL et al. JAMA 2019 Apr 9

Vitamin D3 supplementation, compared with placebo, did not result in significant improvement in relapse-free or progression-free survival in two new trials.


Perioperative Chemotherapy for Resectable Gastric Cancer

David H. Ilson, MD, PhD reviewing Al-Batran S-E et al. Lancet 2019 Apr 10

The FLOT regimen is a new standard of care for patients who can tolerate triplet chemotherapy.


Prolonging Response in Acute Myeloid Leukemia

Michael E. Williams, MD, ScM reviewing Huls G et al. Blood 2019 Mar 28

Disease-free survival was longer with maintenance azacitidine than with observation in older patients who responded to induction chemotherapy.


Archiv
Seite von 81
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer?

William J. Gradishar, MD reviewing Turner NC et al. N Engl J Med 2018 Oct 20

Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.


Immunotherapy for Breast Cancer Has Arrived

William J. Gradishar, MD reviewing Schmid P et al. N Engl J Med 2018 Oct 20

Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.


Brigatinib for ALK-Positive, Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Camidge DR et al. N Engl J Med 2018 Sep 25

Progression-free survival was prolonged with front-line brigatinib versus crizotinib.


Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

Anne S. Tsao, MD reviewing Horn L et al. N Engl J Med 2018 Sep 25

Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.


A New Standard of Care for Squamous Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. N Engl J Med 2018 Sep 25

Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.


Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2018 Sep 25

Two-year overall survival was significantly improved with durvalumab versus placebo.


Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer

William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5

Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.


Olaparib plus Abiraterone for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Clarke N et al. Lancet Oncol 2018 Jul

Progression-free survival was significantly longer with olaparib than with placebo.


Combination Immunotherapy for Metastatic Melanoma with Brain Metastases

Sunandana Chandra, MD, MS reviewing Tawbi HA et al. N Engl J Med 2018 Aug 23, Turajlic S and Larkin J. N Engl J Med 2018 Aug 23

Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.